COPN.SWCOPN.SWSIX

Overview Intelligence Charts News Fundamentals Key Metrics Financials Growth Insiders

Latest News

feeds.newsfilecorp.com

Cosmo Announces Strategic R&D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett's Esophagus

Dublin, Ireland--(Newsfile Corp. - March 5, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE:

feeds.newsfilecorp.com

Cosmo Pharmaceuticals Announces Private Placement of Treasury Shares

Dublin, Ireland--(Newsfile Corp. - February 3, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE:

feeds.newsfilecorp.com

Invitation to Cosmo's Full Year 2025 Financial Results Webcast on 9 March 2026

Dublin, Ireland--(Newsfile Corp. - January 28, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE:

feeds.newsfilecorp.com

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR

feeds.newsfilecorp.com

Cosmo Announces Breakthrough Phase III Topline Results from Scalp 1 and Scalp 2 for Clascoterone 5% Solution in Male Hair Loss, Showing up to 539% Relative Improvement in Target-Area Hair Count vs Placebo; US and EU Submissions are Underway

Ad hoc announcement pursuant to Art. 53 LR

prnewswire.com

Cosmo y Glenmark anuncian la autorización de comercialización de Winlevi®

/PRNewswire/ -- Cosmo Pharmaceuticals N.V. (SIX: COPN) ("Cosmo") y Glenmark Pharmaceuticals Limited (Glenmark), anunciaron que la Comisión Europea (CE) ha

feeds.newsfilecorp.com

Winlevi(R) Receives Regulatory Approval in Brazil - Expanding Global Access to a Breakthrough Acne Treatment

Dublin, Ireland--(Newsfile Corp. - November 14, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance